Wells Fargo & Company Begins Coverage on Beta Bionics (NASDAQ:BBNX)

Analysts at Wells Fargo & Company began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $28.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 28.68% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Bank of America raised their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Wall Street Zen raised shares of Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. William Blair assumed coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Finally, The Goldman Sachs Group lifted their target price on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $22.91.

Beta Bionics Trading Down 1.9%

Shares of BBNX stock traded down $0.43 on Wednesday, reaching $21.76. 906,848 shares of the company’s stock were exchanged, compared to its average volume of 1,191,196. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The stock has a market capitalization of $978.98 million, a PE ratio of -13.19 and a beta of 3.37. The company’s fifty day simple moving average is $17.98 and its 200 day simple moving average is $14.29.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million for the quarter. As a group, sell-side analysts predict that Beta Bionics will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Beta Bionics

In related news, insider Steven Russell sold 4,221 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the completion of the transaction, the insider owned 169,628 shares of the company’s stock, valued at $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,375 shares of Beta Bionics stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $83,606.25. Following the completion of the transaction, the insider owned 180,040 shares in the company, valued at $3,440,564.40. This represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 107,327 shares of company stock valued at $2,070,421 over the last quarter. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Beta Bionics

Large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC bought a new stake in shares of Beta Bionics in the 2nd quarter valued at about $2,524,000. Bank of America Corp DE bought a new position in shares of Beta Bionics during the 2nd quarter worth approximately $8,566,000. Man Group plc purchased a new stake in Beta Bionics during the second quarter valued at approximately $419,000. Legal & General Group Plc purchased a new stake in Beta Bionics during the second quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics in the second quarter valued at approximately $172,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment improved. Truist Financial raised its price target from $23 to $28 and maintained a “Buy” rating, while Wells Fargo reportedly upgraded Beta Bionics to “Strong Buy” and set a $28 target. These targets imply continued upside from the recent trading level. Beta Bionics analyst and stock information
• Positive Sentiment: Potential product expansion remains a longer-term catalyst. Beta Bionics plans to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor, with a combined system expected to launch in the fourth quarter of 2026. The agreement could broaden customer choice and strengthen the company’s position in automated diabetes management. Beta Bionics and Senseonics integration announcement
• Neutral Sentiment: Multiple law firms repeated the same class-action announcement. The lawsuit covers investors who purchased shares during a stated 2025–2026 class period, with a November 3, 2026 deadline to seek lead-plaintiff status. The numerous notices largely add publicity rather than new legal developments, although they keep the issue in focus. Pomerantz Beta Bionics class-action notice
• Negative Sentiment: Litigation raises regulatory and financial risks. Allegations center on claims that Beta Bionics did not adequately disclose an FDA Form 483 and more than 18,000 iLet complaints before later disclosures reportedly pressured the stock. The allegations have not been proven, but potential legal costs, reputational damage and renewed scrutiny of iLet’s regulatory compliance weigh on sentiment. Johnson Fistel Beta Bionics investor alert
• Negative Sentiment: Insider selling added a modest bearish signal. Director Christy Jones sold 6,430 shares for about $147,890, reducing her holdings by approximately 24.7%. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan, it is less informative than discretionary selling. SEC insider transaction filing

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.